Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 47,709 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 47,709 shares of Enliven Therapeutics stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $25.04, for a total transaction of $1,194,633.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Monday, March 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.56, for a total transaction of $210,720.00.
• On Thursday, January 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.69, for a total transaction of $188,280.00.

Enliven Therapeutics Stock Down 5.4 %

Shares of NASDAQ:ELVN opened at $19.94 on Tuesday. The company has a market cap of $821.53 million, a PE ratio of -9.10 and a beta of 1.06. The company’s 50-day moving average price is $16.88 and its 200 day moving average price is $14.25. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, equities analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Institutional Trading of Enliven Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC bought a new stake in shares of Enliven Therapeutics during the 1st quarter worth about $36,000. Ameritas Investment Partners Inc. bought a new stake in shares of Enliven Therapeutics during the 2nd quarter worth about $39,000. AJOVista LLC bought a new stake in shares of Enliven Therapeutics during the 4th quarter worth about $28,000. Royal Bank of Canada raised its position in shares of Enliven Therapeutics by 532.7% during the 2nd quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock worth $63,000 after buying an additional 2,589 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Enliven Therapeutics during the 4th quarter worth about $66,000. 95.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Mizuho initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective on the stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.